Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare ConferenceBusiness Wire • 11/03/20
NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various CancersPRNewsWire • 10/15/20
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast CancerBusiness Wire • 10/05/20
Robbins Geller Rudman & Dowd LLP Announces Jury Verdict Finding Puma Biotechnology and CEO Alan Auerbach Committed Securities Fraud Results in Damages Three to Six Times Higher Than the Company ClaimedBusiness Wire • 09/09/20
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceBusiness Wire • 09/08/20
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of OncologyBusiness Wire • 08/19/20
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical CancersBusiness Wire • 07/27/20
Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus NetworkBusiness Wire • 07/21/20
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast CancerBusiness Wire • 07/16/20
Puma Biotechnology Clears Technical Benchmark, Hitting 80-Plus RS RatingInvestors Business Daily • 07/08/20
Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/20
Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?Zacks Investment Research • 05/14/20
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be PrematureThe Motley Fool • 04/01/20